MS37452

Research use only, not for human use.

MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 μM).

MS37452 is a competitive inhibitor of CBX7 chromodomain binding to H3K27me3 (Ki = 43 μM).

MS37452 (125-500 μM; 12 hours) significantly increases INK4A/ARF transcript levels up to 25% and 60% for 250 μM and 500 μM, respectively, as compared to the DMSO control.MS37452 (250 μM; 2 hours) treats human PC3 prostate cancer cells for 2 hours reducing CBX7 occupancy across the INK4A/ARF locus.MS37452 (200 μM; 5 days) combined with doxorubicin results in consistently decreased cell viability compared to DMSO treated and single drug treatment.MS37452 (200 μM; 5 days), which is a CBX7 chromodomain inhibitor (CBX7i), in combination with doxorubicin is a novel therapeutic strategy. RT-PCR Cell Line:PC3 cells Concentration:125-500 μM Incubation Time:12 hours Result:Up-regulated INK4A/ARF expression up to 25% and 60% for 250 μM and 500 μM, respectively.Cell Viability Assay Cell Line:Glioblastoma multiforme (GBM) U118MG cells Concentration: PRT4165 40 μM, PTC209 200 nM, DZnep 25 μM, GSK343 400 nM, MS37452 200 μM, Doxorubicin 200 nM, temozolomide 50 μM, SAHA 1 μM Incubation Time:5 days Result:Identified several combinations that resulted in consistently decreased cell viability compared to DMSO treated and single drug treatment: SAHA/TMZ and MS37452/doxorubicin.

——

——

Others

Other Targets

Parasite|MmpL3

——

——

423748-02-1

398.459

C22H26N2O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (250.97 mM)

COc1cccc(C(=O)N2CCN(CC2)C(=O)COc2cccc(C)c2)c1OC

——

(-20℃)

With Ice Pack

≥ 2 years